A discounted cash flow (DCF) analysis for Retrophin, conducted by Deutsche Bank, with a DCF value of $52. The document includes financial projections from 2015 to 2029, tax rates, operating free cash flow, growth rates, discount periods and factors, and present value of cash flows. It also details terminal growth rate, discount rate, net present value (NPV) of cash flows, and other financial metrics.
documents/vol00010-efta01457578-pdf.pdf
{"title":"DB BIOTECH: RETROPHIN DCF","key_people":["Robyn Karnauskas"],"document_date":"2015-05-27","document_type":"tabular","key_organizations":["Deutsche Bank","Retrophin"]}